Nucleases

Nucleases

ChemDiv offers high throughput screening (HTS) service
Nucleases research platform

• Nuclease assay development on demand

• FRET/fluorescence HTS assays.

• Our support in compound selection based on your research project

• Screening from 10000 compound sets up to 300000 and more

• A quick start of your research project

• 25 years of experience

Nuclease (nucleotide/nucleic acid cleaving enzyme) mutations compromise the immune system and result in genetic instability: for example, mutations in XPG gene ERCC5 lead to Cockayne syndrome or cancer-prone skin sensitivity. APE1 inhibitor AR03 stopped AP cleavage in glioblastoma cells in vitro, indicating oncotherapy potential for APE1 as a target. Exo1 levels are significantly elevated in hepatocellular carcinoma cells and are an independent risk factor, suggesting Exo1 as a future target. RAD51 is overexpressed in numerous cancers, with anti-RAD51 small RNA increasing the chemosensitivity to doxorubicin in soft tissue sarcoma. 

The usual nuclease investigation method is a fluorescence assay – either a standard one or FRET (difference between the two is shown in figure 1). FRET

• a donor fluorophore gets energy

• this energy is then passed on to an acceptor fluorophore

• acceptor emits a measurable signal

• suited for HTS due to being easy to automate
  
  
  

Figure 1. A Jablonski diagram illustrating the difference between fluorescence (A) and FRET (B). From ‘Fluorescent Proteins as Genetically Encoded FRET Biosensors in Life Sciences’, 2015, Hochreiter et al. 

Owing to the role of nucleases in cancer, they serve as potential targets and require research. 

ChemDiv offer a nuclease assay (including the aforementioned APE1, Exo1, RAD51) for you in a timely and cost-effective manner.